AbbVie Inc (ABBV)vsSi-Bone Inc (SIBN)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
SIBN
Si-Bone Inc
$12.39
+3.86%
HEALTHCARE · Cap: $546.85M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 30339% more annual revenue ($61.16B vs $200.93M). ABBV leads profitability with a 6.9% profit margin vs -9.4%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
SIBN
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+54.3%
Fair Value
$32.74
Current Price
$12.39
$20.35 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
15.0% revenue growth
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -11.0% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : SIBN
The strongest argument for SIBN centers on Revenue Growth. Revenue growth of 15.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : SIBN
The primary concerns for SIBN are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while SIBN is a turnaround play — different risk/reward profiles.
SIBN carries more volatility with a beta of 0.77 — expect wider price swings.
SIBN is growing revenue faster at 15.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 32/100). SIBN offers better value entry with a 54.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Si-Bone Inc
HEALTHCARE · MEDICAL DEVICES · USA
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and internationally. The company is headquartered in Santa Clara, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?